[Current status of nuclear medicine. Clinical application of FDG-PET for cancer diagnosis. Colorectal cancer].
In Japan, colorectal cancer is the third most common cause of death from cancer. The recurrence rate after curative surgical treatment for colorectal cancer has been estimated at 30-40%, most frequently occurring within 3 years. Therefore, more accurate staging of recurrent colorectal cancer is required for more appropriate management decisions. This article focuses on the clinical value of PET with [18F]fluorodeoxyglucose (FDG) in the diagnosis of recurrent and primary colorectal cancers. The technical issues in clinical practice and the cost-effectiveness of FDG-PET in staging recurrent colorectal cancer will be covered.
Ito
Kengo
K
Kato
Takahsi
T
D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D003937:Diagnosis, Differential; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D008279:Magnetic Resonance Imaging; D008297:Male; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18